外泌体传递的lncRNA H19抑制垂体腺瘤生长
本研究探讨外泌体携带的lncRNA H19能否跨细胞膜转运并抑制垂体瘤生长。通过GH3细胞异种移植模型及200例健康者和206例垂体瘤患者血清外泌体H19检测,发现外泌体H19可抑制远端肿瘤细胞生长,且患者外泌体H19水平显著低于健康者。外泌体H19通过抑制4E-BP1磷酸化发挥作用,卡麦角林可上调H19并与之协同。
要点
- 外泌体H19可跨细胞膜转运并抑制远端垂体瘤细胞生长
- 垂体瘤患者各亚型外泌体H19水平均显著低于健康者
- 外泌体H19通过抑制mTORC1底物4E-BP1磷酸化发挥作用
核心结论
- 外泌体H19通过抑制4E-BP1磷酸化抑制远端垂体瘤生长,血浆外泌体H19可能成为预测泌乳素瘤治疗反应的重要生物标志物。
研究设计与样本
- 使用空载或H19过表达的慢病毒GH3细胞建立异种移植模型,并通过透射电镜、纳米颗粒追踪和Western blotting鉴定分离的外泌体。
- 采用超速离心和定量实时PCR检测200例健康受试者和206例不同亚型垂体瘤患者血清外泌体H19表达水平。
主要发现
- 转染外泌体H19可抑制远端肿瘤细胞生长,且外泌体H19能跨细胞膜转运发挥抑制作用。
- 卡麦角林增加H19表达,并与外泌体H19产生协同治疗效应。
- 外泌体H19抑制mTORC1底物4E-BP1的磷酸化。
- 所有亚型垂体瘤患者的外泌体H19表达水平均显著低于健康受试者。
- 血浆外泌体H19水平变化可能与患者预后或药物反应相关。
临床怎么用
- 血浆外泌体H19可能作为预测泌乳素瘤患者药物治疗反应的生物标志物。
- 外泌体H19与卡麦角林联合可能具有协同治疗潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Our previous study demonstrated that the expression of long noncoding RNA (lncRNA) H19 was frequently downregulated in human primary pituitary adenomas and negatively correlated with tumor progression. However, the role of exosomal lncRNA H19 in the inhibition of pituitary tumor growth remains unclear. OBJECTIVE: To investigate whether exosomal H19 could be transported across the cell membrane to exert its inhibitory effect on pituitary tumor growth. DESIGN: Empty lentivirus GH3 cells with or without H19 overexpression were used to establish a xenograft model. Isolated exosomes were identified by transmission electron microscopy, nanoparticle tracking, and Western blotting. The expression levels of serum exosomal H19 from 200 healthy subjects and 206 patients with various subtypes of pituitary tumors were detected by ultracentrifugation and quantitative real-time PCR. RESULTS: The growth of distal tumor cells was inhibited by transferring exosomal H19, which could be transported through cell membrane and exert its inhibitory effect. Cabergoline increased H19 expression and played a synergic therapeutic effect with exosomal H19. Exosomal H19 inhibited phosphorylation of the mTORC1 substrate 4E-BP1. Of note, the expression level of exosomal H19 in the patients with all subtypes of pituitary tumors was significantly lower than that in the healthy subjects. The change of plasma exosomal H19 level may be correlated with the prognosis or drug response of the patients. CONCLUSION: Exosomal H19 inhibits the growth of distal pituitary tumors through inhibiting 4E-BP1 phosphorylation. Plasma exosomal H19 may serve as an important biomarker for predicting medical responses of patients with prolactinomas.
引用
- Zhang Y, Liu YT, Tang H, et al. Exosome-Transmitted lncRNA H19 Inhibits the Growth of Pituitary Adenoma. J Clin Endocrinol Metab. 2019. PMID: 31369093. doi:10.1210/jc.2019-00536
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。